(Q38685592)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26725904%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

HBV: Do I treat my immunotolerant patients? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26725904%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author

George Papatheodoridis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26725904%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Jiannis Vlachogiannakos

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26725904%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

1 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26725904%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26725904%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

36 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26725904%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

93-99

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26725904%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B Virus Infection

3 March 2020

cites work

1 reference

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors

21 January 2018

1 reference

Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.

21 January 2018

1 reference

Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy.

21 January 2018

1 reference

Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities

21 January 2018

1 reference

Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B.

21 January 2018

1 reference

Liver biopsy findings in chronic hepatitis B.

21 January 2018

1 reference

Impaired antigen processing and presentation machinery is associated with immunotolerant state in chronic hepatitis B virus infection

21 January 2018

1 reference

Pathogenetic and antiviral immune responses against hepatitis B virus

21 January 2018

1 reference

Hepatitis B precore protein: pathogenic potential and therapeutic promise

21 January 2018

1 reference

Fulminant hepatitis B: induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen

21 January 2018

1 reference

Hepatitis B virus mutants with precore-region defects in two babies with fulminant hepatitis and their mothers positive for antibody to hepatitis B e antigen

21 January 2018

1 reference

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

Chronic hepatitis B: update 2009

21 January 2018

1 reference

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

21 January 2018

1 reference

Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome

21 January 2018

1 reference

The clinical significance of persistently normal ALT in chronic hepatitis B infection

21 January 2018

1 reference

Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT.

21 January 2018

1 reference

Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B.

21 January 2018

1 reference

Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients.

21 January 2018

1 reference

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation

21 January 2018

1 reference

Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease

21 January 2018

1 reference

A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection

21 January 2018

1 reference

Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus

21 January 2018

1 reference

Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare

21 January 2018

1 reference

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

21 January 2018

1 reference

Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.

21 January 2018

1 reference

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors

21 January 2018

1 reference

Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial

21 January 2018

1 reference

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.

21 January 2018

1 reference

Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?

21 January 2018

1 reference

Current treatment indications and strategies in chronic hepatitis B virus infection.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26725904%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference